Search PubMed⌕ Search

Biomedical subjects

D H Frankel

Publications and source records attributed to D H Frankel.

At least 19 recordsLinked to original sources
PubMed1996

Skin cancer.

Explore the source record for details and available documents.

Humans↗
PubMed1992

New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin. Implications and recommendations for follow-up.

BACKGROUND: Rational follow-up guidelines for skin cancer patients should be based on the risk of three separate events: cancer recurrence, cancer metastasis, and the development of subsequent skin cancers. However, currently no guidelines exist for follow-up of patients with squamous cell carcinoma of the skin (SCC), which take into account all three of these risks. OBJECTIVE: The purpose of this study is to establish rational minimum guidelines for follow-up of patients with SCC. To do this, we first must determine the risk of SCC patients for the development of subsequent skin cancers. Combining these data with previously published data on SCC recurrence and SCC metastasis, we then propose guidelines for follow-up of patients with SCC. METHODS: We followed up 101 SCC patients on a yearly basis for 5 years after treatment and recorded the date and site of subsequent nonmelanoma skin cancers (NMSCs). RESULTS: Thirty percent of SCC patients developed additional SCCs and 52% developed subsequent NMSCs within 5 years of therapy for their first SCC. Patients showing the highest risk of subsequent NMSC were those presenting with multiple SCC, SCC greater than 1 cm in diameter, SCC requiring more than 1 Mohs surgery layer to remove, or SCC occurring on the scalp, ear, nose, or extremities. One hundred percent of subsequent NMSCs were detected by the fourth year of follow-up; 54% of these occurred within the first year of follow-up. CONCLUSION: After combining our data with previously published studies of SCC recurrence and metastasis, we recommend that all patients with SCC be followed up for at least 4 years after treatment. Moreover, because most subsequent NMSCs, SCC recurrences, and SCC metastases developed early in the follow-up period, we recommend that patients be reexamined at least every 3 months during the first year of follow-up and every 6 months thereafter. It must be stressed that these are meant as minimum follow-up guidelines.

Carcinoma, Squamous Cell↗
PubMed1989

Hendersonula toruloidea infection in man. Index cases in the non-endemic North American host, and a review of the literature.

Hendersonula toruloidea (HT) is a dematiaceous fungus that is an endemic human pathogen in tropical and subtropical countries. Infection with this fungus is often clinically indistinguishable from Trichophyton rubrum or other dermatophytoses. However, because HT will not grow on standard cycloheximide containing fungal media, and because HT is usually resistant to standard anti-fungal therapies, we believe that HT is a more common cause of 'recalcitrant dermatophytosis' in the United States than is currently recognized. HT may be especially prevalent among immigrant patients from endemic countries. We report the first cases of HT to occur in a non-endemic region of the United States. This suggests that HT may become a significant pathogen in the native American host as well. Moreover, we report the first case of a tinea capitis-like infection due to HT.

Adult↗